Assess whether pediatric studies are necessary or waivable (364f9f)

Situation

A boxed-warning proposal from the review division put scientific-advice briefing book in front of CMC change-control owner in a rare-disease team designing a pediatric plan. This Pharma & Life Sciences / CMC and Development Pathways close is pediatric studies are necessary from scientific-advice briefing book, and the live options are Pediatric studies are necessary, Waivable.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose Pediatric studies are necessary / Waivable using scientific-advice briefing book after a boxed-warning proposal from the review division.

Hypotheses to test

• The population in scientific-advice briefing book is the one a boxed-warning proposal from the review division named, so Pediatric studies are necessary follows for this CMC and Development Pathways file.
• The population in scientific-advice briefing book is adjacent only to a boxed-warning proposal from the review division; Waivable is the honest Pharma & Life Sciences call.
• A rare-disease team designing a pediatric plan already contained a boxed-warning proposal from the review division before scientific-advice briefing book arrived; no new CMC and Development Pathways path.
• Provenance on scientific-advice briefing book after a boxed-warning proposal from the review division is broken; do not pick Pediatric studies are necessary or Waivable yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether scientific-advice briefing book supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• For this Pharma & Life Sciences CMC and Development Pathways file, read scientific-advice briefing book against a boxed-warning proposal from the review division and write the one fact that would move pediatric studies are necessary for CMC change-control owner.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (scientific-advice briefing book after a boxed-warning proposal from the review division). The follow-on CMC and Development Pathways action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.